Jiangsu Recbio Technology Future Growth
Future criteria checks 0/6
Jiangsu Recbio Technology's earnings are forecast to decline at 3.4% per annum. EPS is expected to decline by 4.1% per annum.
Key information
-3.4%
Earnings growth rate
-4.1%
EPS growth rate
| Biotechs earnings growth | 35.3% |
| Revenue growth rate | n/a |
| Future return on equity | -90.7% |
| Analyst coverage | Low |
| Last updated | 01 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 30 | -572 | -862 | -638 | N/A |
| 9/30/2023 | 19 | -609 | -882 | -674 | N/A |
| 6/30/2023 | 8 | -646 | -901 | -711 | N/A |
| 3/31/2023 | 7 | -684 | -895 | -645 | N/A |
| 12/31/2022 | 5 | -723 | -888 | -580 | N/A |
| 9/30/2022 | 6 | -673 | -852 | -540 | N/A |
| 6/30/2022 | 8 | -677 | -842 | -512 | N/A |
| 3/31/2022 | 7 | -667 | -777 | -492 | N/A |
| 12/31/2021 | 6 | -658 | -711 | -473 | N/A |
| 9/30/2021 | 3 | -627 | -666 | -369 | N/A |
| 12/31/2020 | 1 | -179 | -209 | -70 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2179 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2179 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2179 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2179's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2179's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2179 is forecast to be unprofitable in 3 years.